GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dicerna Pharmaceuticals Inc (NAS:DRNA) » Definitions » Financial Strength

Dicerna Pharmaceuticals (Dicerna Pharmaceuticals) Financial Strength : 0 (As of Sep. 2021)


View and export this data going back to 2014. Start your Free Trial

What is Dicerna Pharmaceuticals Financial Strength?

Dicerna Pharmaceuticals has the Financial Strength Rank of 0.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

Dicerna Pharmaceuticals did not have earnings to cover the interest expense. Dicerna Pharmaceuticals's debt to revenue ratio for the quarter that ended in Sep. 2021 was 0.26. As of today, Dicerna Pharmaceuticals's Altman Z-Score is 1.64.


Competitive Comparison of Dicerna Pharmaceuticals's Financial Strength

For the Biotechnology subindustry, Dicerna Pharmaceuticals's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dicerna Pharmaceuticals's Financial Strength Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dicerna Pharmaceuticals's Financial Strength distribution charts can be found below:

* The bar in red indicates where Dicerna Pharmaceuticals's Financial Strength falls into.



Dicerna Pharmaceuticals Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Dicerna Pharmaceuticals's Interest Expense for the months ended in Sep. 2021 was $-0.0 Mil. Its Operating Income for the months ended in Sep. 2021 was $-20.3 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2021 was $59.5 Mil.

Dicerna Pharmaceuticals's Interest Coverage for the quarter that ended in Sep. 2021 is

Dicerna Pharmaceuticals did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Dicerna Pharmaceuticals's Debt to Revenue Ratio for the quarter that ended in Sep. 2021 is

Debt to Revenue Ratio=Total Debt (Q: Sep. 2021 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(4.895 + 59.525) / 251.816
=0.26

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Dicerna Pharmaceuticals has a Z-score of 1.64, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of 1.64 is in distress zone. This implies bankrupcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dicerna Pharmaceuticals  (NAS:DRNA) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Dicerna Pharmaceuticals has the Financial Strength Rank of 0.


Dicerna Pharmaceuticals Financial Strength Related Terms

Thank you for viewing the detailed overview of Dicerna Pharmaceuticals's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Dicerna Pharmaceuticals (Dicerna Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
75 Hayden Avenue, Lexington, MA, USA, 02421
Dicerna Pharmaceuticals is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, cardiovascular diseases, cancers, and other liver problems. The company uses its ribonucleic acid interference technology platform to develop its products. In addition, Dicerna's proprietary GalXC technology focuses on silencing disease-causing genes. The product candidates are nedosiran (for primary hyperoxaluria), belcesiran (for genetic liver disease), DCR-PCSK9 (for cardiovascular disease), and RG6346 (for hepatitis B virus) among others. Dicerna generates revenue by forming collaborative relationships with pharmaceutical companies such as Eli Lilly, Roche, Novo Nordisk, and others.
Executives
Bob D Brown officer: See Remarks 87 CAMBRIDGEPARK DRIVE CAMBRIDGE MA 02140
Shreeram Aradhye officer: EVP & Chief Medical Officer C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Marc D Kozin director
Douglas Fambrough director, officer: President and CEO C/O DICERNA PHARMACEUTICALS, INC., 75 HAYDEN AVENUE, LEXINGTON MA 02421
James B Weissman officer: Chief Operating Officer & EVP C/O DICERNA PHARMACEUTICALS, INC. 33 HAYDEN AVENUE LEXINGTON MA 02421
Regina M. Paglia officer: Chief Human Resources Officer C/O DICERNA PHARMACEUTICALS, INC. 33 HAYDEN AVENUE LEXINGTON MA 02421
Robert D. Ciappenelli officer: Chief Commercial Officer DICERNA PHARMACEUTICALS, INC. 87 CAMBRIDGEPARK DRIVE CAMBRIDGE MA 02140
Adam Koppel director C/O BROOKSIDE CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON ST, BOSTON MA 02116
Anna Protopapas director MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Stephen K Doberstein director 129 ELSIE STREET, SAN FRANCISCO CA 94110
Patrick M. Gray director C/O CIVITAS SOLUTIONS, INC. 313 CONGRESS STREET, 6TH FLOOR BOSTON MA 02210
J Kevin Buchi director 41 MOORES ROAD, FRAZER PA 19355
Martin I Freed director 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Cynthia Smith director 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Stephen J Hoffman director C/O SKYLINE VENTURES, 525 UNIVERSITY AVE., SUITE 1350, PALO ALTO CA 94301

Dicerna Pharmaceuticals (Dicerna Pharmaceuticals) Headlines

From GuruFocus

Dicerna to Report Third Quarter 2021 Financial Results on Nov. 9, 2021

By Business Wire Business Wire 11-02-2021